A detailed history of Nordwand Advisors, LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Nordwand Advisors, LLC holds 3,029,824 shares of NVCR stock, worth $51.1 Million. This represents 12.67% of its overall portfolio holdings.

Number of Shares
3,029,824
Previous 1,515,000 99.99%
Holding current value
$51.1 Million
Previous $26 Billion 82.48%
% of portfolio
12.67%
Previous 11.32%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$15.61 - $23.34 $23.6 Million - $35.4 Million
1,514,824 Added 99.99%
3,029,824 $47.4 Billion
Q4 2022

Mar 07, 2023

SELL
$63.98 - $85.37 $486 Million - $649 Million
-7,599,361 Reduced 83.38%
1,515,000 $111 Billion
Q4 2022

Jan 26, 2023

BUY
$63.98 - $85.37 $583 Million - $778 Million
9,114,361 New
9,114,361 $0

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.77B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Nordwand Advisors, LLC Portfolio

Follow Nordwand Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordwand Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nordwand Advisors, LLC with notifications on news.